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Background / Objectives 
 
Novel HPV assays intended for cervical screening use must be evaluated in 
accordance with International guidelines for Human Papilloma Virus test 
requirements for cervical cancer screening. The CLART HPV4S assay (CLART4S, 
Genomica, Madrid, Spain) is a PCR based microarray assay targeting the L1 region, 
and the first full-genotyping assay to detect oncogenic HPV genotypes (16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59, 68) and three non-oncogenic-HPV genotypes (6, 
11, 66) to achieve fulfillment of international validation criteria using SurePath 
screening samples. Here we present the outcome of the validation of this novel full-
genotyping assay on SurePath collected screening samples, using the GP5+/6+ PCR 
assay (GP5/6) as a comparator/reference. The genotype concordance between 




To assess the performance of the CLART4S assay, SurePath screening samples 
from women 30 years and above participating in the Danish cervical cancer 
screening program were collected at Copenhagen University hospital, Hvidovre. For 
the clinical sensitivity analysis, 81 samples from women with confirmed CIN2 or 
greater were collected. For the clinical specificity analysis, 1184 samples from 
 475/490 
women with less than CIN2 histology were collected. The assay results were 
compared to that of the GP5/6 assay in collaboration with Karolinska Institutet, 
Stockholm. The laboratory performance element involved testing 540 individual 
samples with known GP5/6 results. The inter-laboratory agreement was performed in 
collaboration with the Scottish HPV Reference Laboratory in Edinburgh, Scotland. 
 
Conclusion 
The relative sensitivity of CLART4S was 91.3% (GP5/6=92.6%) and relative 
specificity was 90.7% (GP5/6=91.0%). The CLART4S assay was shown to be non-
inferior to that of GP5/6 for both sensitivity (p=0.00) and specificity (p=0.02). The 
genotype specific concordance between CLART4S and GP5/6 was good for 12 
oncogenic HPV types. The Kappa value for intra-laboratory reproducibility was 0.84 
(lower confidence bound 0.92) and for the inter-laboratory agreement the kappa 
value was 0.72 (lower confidence bound 0.87). 
References 
This is the first report on the clinical validation study of a full-genotyping HPV assay 
applied to SurePath collected samples. Using GP5/6 as comparator, the CLART4S 
performed well and met the International guidelines for sensitivity, specificity, intra-
laboratory reproducibility and inter-laboratory agreement. The CLART HPV4S assay 
is therefore a good candidate for use in cervical cancer screening programs, 
especially programs utilizing genotype information in the screening algorithms. 
 
 
 
 
 
 
